| Acinetobacter baumannii: emergence of a successful pathogen AY Peleg, H Seifert, DL Paterson Clinical microbiology reviews 21 (3), 538-582, 2008 | 3484 | 2008 |
| Hospital-acquired infections due to gram-negative bacteria AY Peleg, DC Hooper New England Journal of Medicine 362 (19), 1804-1813, 2010 | 1450 | 2010 |
| Common infections in diabetes: pathogenesis, management and relationship to glycaemic control AY Peleg, T Weerarathna, JS McCarthy, TME Davis Diabetes/metabolism research and reviews 23 (1), 3-13, 2007 | 489 | 2007 |
| Treatment of Acinetobacter Infections J Fishbain, AY Peleg Clinical infectious diseases 51 (1), 79-84, 2010 | 425 | 2010 |
| Medically important bacterial–fungal interactions AY Peleg, DA Hogan, E Mylonakis Nature Reviews Microbiology 8 (5), 340-349, 2010 | 419 | 2010 |
| Risk Factors, Clinical Characteristics, and Outcome of Nocardia Infection in Organ Transplant Recipients: A Matched Case-Control Study AY Peleg, S Husain, ZA Qureshi, FP Silveira, M Sarumi, KA Shutt, ... Clinical Infectious Diseases 44 (10), 1307-1314, 2007 | 358 | 2007 |
| Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report AY Peleg, BA Potoski, R Rea, J Adams, J Sethi, B Capitano, S Husain, ... Journal of antimicrobial chemotherapy 59 (1), 128-131, 2007 | 325 | 2007 |
| Phenotypic detection of carbapenem-susceptible metallo-β-lactamase-producing gram-negative bacilli in the clinical laboratory C Franklin, L Liolios, AY Peleg Journal of clinical microbiology 44 (9), 3139-3144, 2006 | 316 | 2006 |
| Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii AY Peleg, J Adams, DL Paterson Antimicrobial agents and chemotherapy 51 (6), 2065-2069, 2007 | 309 | 2007 |
| Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics AY Peleg, S Jara, D Monga, GM Eliopoulos, RC Moellering, E Mylonakis Antimicrobial agents and chemotherapy 53 (6), 2605-2609, 2009 | 261 | 2009 |
| Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody AY Peleg, S Husain, EJ Kwak, FP Silveira, M Ndirangu, J Tran, KA Shutt, ... Clinical infectious diseases 44 (2), 204-212, 2007 | 250 | 2007 |
| Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a … PNA Harris, PA Tambyah, DC Lye, Y Mo, TH Lee, M Yilmaz, TH Alenazi, ... Jama 320 (10), 984-994, 2018 | 235 | 2018 |
| Management of meningitis due to antibiotic-resistant Acinetobacter species BN Kim, AY Peleg, TP Lodise, J Lipman, J Li, R Nation, DL Paterson The Lancet infectious diseases 9 (4), 245-255, 2009 | 234 | 2009 |
| Dissemination of the Metallo-β-Lactamase Gene blaIMP-4 among Gram-Negative Pathogens in a Clinical Setting in Australia AY Peleg, C Franklin, JM Bell, DW Spelman Clinical infectious diseases 41 (11), 1549-1556, 2005 | 231 | 2005 |
| Acinetobacter baumannii: evolution of antimicrobial resistance—treatment options Y Doi, GL Murray, AY Peleg Seminars in respiratory and critical care medicine 36 (1), 85, 2015 | 199 | 2015 |
| Candida albicans hyphal formation and virulence assessed using a Caenorhabditis elegans infection model R Pukkila-Worley, AY Peleg, E Tampakakis, E Mylonakis Eukaryotic cell 8 (11), 1750-1758, 2009 | 178 | 2009 |
| Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus AY Peleg, S Miyakis, DV Ward, AM Earl, A Rubio, DR Cameron, S Pillai, ... PloS one 7 (1), e28316, 2012 | 174 | 2012 |
| Prokaryote–eukaryote interactions identified by using Caenorhabditis elegans AY Peleg, E Tampakakis, BB Fuchs, GM Eliopoulos, RC Moellering, ... Proceedings of the National Academy of Sciences 105 (38), 14585-14590, 2008 | 167 | 2008 |
| Reduced Susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection AY Peleg, D Monga, S Pillai, E Mylonakis, RC Moellering Jr, ... The Journal of infectious diseases 199 (4), 532-536, 2009 | 163 | 2009 |
| Carbapenem resistance in Acinetobacter baumannii: laboratory challenges, mechanistic insights and therapeutic strategies I Abbott, GM Cerqueira, S Bhuiyan, AY Peleg Expert review of anti-infective therapy 11 (4), 395-409, 2013 | 159 | 2013 |
